Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. MSFT
6. NAVN
7. DFTX
8. CNC
9. KFY
10. SPY

Go back to Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Terns Pharmaceuticals (TERN) PT Raised to $30 at Jefferies Following +16% Gain Today

September 9, 2024 4:00 PM EDT

Jefferies analyst Akash Tewari raised the price target on Terns Pharmaceuticals (NASDAQ: TERN) to $30.00 (from $22.00) while maintaining a Buy rating.

The analyst comments "TERN-601 Ph1 readout in-line w/ our bull case: ~5% pbo-adj WL & ~88% nausea/~78% vomiting at the highest 740mg qd dose.... More

Terns Pharmaceuticals Inc. (TERN) Climbs 29% Following Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

September 9, 2024 8:07 AM EDT

Terns Pharmaceuticals Inc. (NASDAQ: TERN) Climbs 29% Following Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted)Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with... More